Reimbursement Drives Drug Innovation

A payer policy that enlarges guaranteed market access — such as China’s National Reimbursement Drug List reform — can quickly change firm incentives, producing big increases in trial quantity and novelty concentrated in exposed disease areas and domestic manufacturers. The reform is empirically tied to an 86% rise in trials and explains roughly 43% of oncology trial growth, while induced innovation effects on future drug availability are much larger than the immediate affordability gains. — This reframes pharmaceutical industrial policy: governments can catalyze domestic R&D not only with subsidies or labs, but by changing reimbursement rules that alter expected market size and returns.